Micro Pharmaceuticals
Market Cap
₹1,252 ₹1,252 Cr.
P/E
12.98
PEG
0.83
PEG = P/E ÷ 5yr Forward EPS CAGR
5yr Forward EPS CAGR Thesis - Base Case

- The thesis comes alive if export conversion, country registrations, Cephalosporin commercialization and domestic product scale-up progress broadly as planned.- The bull path depends on faster export conversion and earlier Cephalosporin commercialization, while the bear path reflects delayed commercialization, weaker export/customer conversion and slower domestic uptake.

Key Ratios

Debt to Equity
Debt to Equity
-
Div Yield (%)
Div Yield (%)
0.29
Individual < 2 lac
Individual < 2 lac
24.35 %
Institutions
Institutions
4.87 %
Market cap
Market cap
1,252 Cr
No. of Shareholders
No. of Shareholders
29,396
OPM (%)
OPM (%)
14.59 %
PE
PE
12.98
Prom Holding
Prom Holding
49.78 %
ROCE (%)
ROCE (%)
16.08
ROE (%)
ROE (%)
12.26
Sales
Sales
694 Cr
  • Lincoln Pharma
  • Bharat Parenterals
  • Jagsonpal Pharma
  • TJI Pharma
Last updated on 13 Aug 2026
  • Lincoln Pharma makes pharmaceutical formulations, ~62% exported to Africa, LatAm/SE Asia, UN tenders and Canada; rest sold in India via 600+ field force.
  • Q1FY27 margin jumped to ~25.6% from 18.6% FY26, but ₹24.26Cr other income was ~47% of EBITDA; underlying rebound unconfirmed.
  • Base acute portfolio shifting toward chronic cardiac, diabetic, dermatology and ENT lines that now carry growth.
  • Cephalosporin at breakeven scaling up; bulk-drug plant started; pushing from 60-plus countries toward 90 with Canada early and EU/TGA pending.
  • Debt-free but ~₹187Cr loans and advances for vendor/inorganic plans remain material recoverability exposure.
  • Everything near term rides on guided ₹1,000Cr in 3 years at 15–18% annual growth after missing ₹750Cr FY26 target.
  • EU GMP reinspection outcome was mid-2026; no update since
    opens EU market entry for three awaiting products.
  • Canada ramp-up ongoing
    lifts revenue beyond ~$4–5M; 23 products signed, five commercialised, six lines approved.
  • Cephalosporin ramp-up FY27
    scales ~₹45Cr plant toward ₹90–100Cr FY27, ₹150Cr over 3 years.
  • Bulk-drug plant scale-up No timeline
    brings 10 approved products toward commercial scale; remaining approvals pending.
  • Inorganic growth exploration No timeline
    sets cash deployment, valuation and related-party exposure.
Price Range

See where the stock is trading versus its 52-week high and low.

Low
440
52W Range
High
770
Timeline

Key company specific updates.

Custom financial statement

Edit rows

Forensics

9 Yes

Positive for this company

2 Neutral

Neutral for this company

6 No

Negative for this company

0 No Data

Insufficient data to analyse

Market Share

0.04 %
(as of Jul 22)
Anti - Diabetes - Market Share
0.15 %
(as of Jul 22)
Anti-Infectives - Market Share
0.80 %
(as of Nov 21)
Anti-Malarial - Market Share
0.10 %
(as of Nov 21)
Blood Related - Market Share
0.02 %
(as of Jul 22)
Cardiovascular - Market Share
0.11 %
(as of Nov 21)
Dermatology - Market Share

Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Operational Metrics

    Select a Metric
    • Domestic Sales Growth - YoY (%)
    • R&D as a % of Total Sales (%)

    Peer Comparison

    Corporate Actions

    Consolidated
    DATE
    DETAILS
    Show More
    Show Less
    Show More
    Show Less

    FAQs on Lincoln Pharmaceuticals Ltd. Business

    Lincoln Pharmaceuticals Ltd specializes in producing and promoting cost-effective therapeutic products such as Tablets, Capsules, Injectables, Syrups, and Ointments.

    Lincoln Pharma major competitors are Bharat Parenterals, Jagsonpal Pharma, Anuh Pharma, Wanbury, Syncom Formulations, Zim Laboratories, Kilitch Drugs(India).
    Market Cap of Lincoln Pharma is ₹1,262 Crs.
    While the median market cap of its peers are ₹949 Crs.

    Lincoln Pharma seems to be financially stable compared to its competitors.
    The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

    Company Filing

    Discussions & Analysis

    Ideas Dashboard
    Results
    Timeline
    Watchlist
    Portfolio
    Alerts
    Stock Screener
    Market
    Raw Material